Genomic Vision’s Technology is Acquired by Department of Cell Biology, Microbiology & Molecular Biology at the University of South Florida to Study Mechanisms of DNA Replication and Replication Stress

BUNNE, France, February 17, 2022– (BUSINESS WIRE) – News of regulation:

Genomic Vision (“Company” – FR0011799907 – GV) (Paris: GV)The biotechnology company, which develops tools and services dedicated to analyzing and monitoring changes in the genome, today announced that the University of South Florida is implementing a full-time molecular combing process using FiberComb, FiberVision S and FiberStudio solutions.

Researchers from the University of South Florida received funding from the National Institutes of Health (NIH) to purchase Genomic Vision technology to implement the company’s replication comb analysis analysis work with the prospect of studying more than 100 samples in the first year of the molecular combing grant.

Genomic Vision Replication Comb Analysis provides accurate readings of the spatial and temporal characteristics of DNA replication, allowing the characterization of universal and targeted genome replication events, providing researchers with critical DNA replication functions such as initiation rate, fork replication speed and fork speed.

In cancer research, these features of DNA replication help in drug development because molecular combing allows a clear understanding of the mechanistic understanding of genomic instability.

Gaining a better understanding of the mechanisms that support the stability of the human genome, including those that function at the junction between replication, recombination, and DNA repair, is a very important part of our program with the NIH, especially with regard to Bloom. DNA helicase syndrome and its interacting factorssaid Professor Christina Schmidt, Professor of Cell and Molecular Biology at the University of South Florida. “Adding molecular combing to our laboratory experience will help us expand our research on how DNA damage, unusual DNA structures, and changes in replisome composition affect DNA replication and lead to genome instability and increased cancer risk“.

Errors in DNA replication are a major cause of mutagenesis and genome instability. Characterization of the mechanisms that control replication dynamics and fork stability in response to replication stress is a major focus of our NIH-assisted program, and the acquisition of this combing technology provides a whole new dimension to our research efforts.said Joseph Dangraval, Associate Professor of Cell and Molecular Biology at the University of South Florida.

“The DNA replication analysis segment is a leading application for our molecular combing technology, enabling research and biotechnology customers to gain accurate readings of the spatial and temporal characteristics of DNA replication.” said Dominique Remy-Ren, CEO of Genomic Vision. “We look forward to working with the University of South Florida to provide new insights for analyzing structural variation and genomic rearrangement in complex genetic disease research and drug development.”

***

ABOUT GENOMIC DENIAL

GENOMIC VISION is a biotechnology company that develops products and services for the analysis (structural and functional) of genome modifications, as well as quality and safety control of these modifications, in particular in genome editing technologies and bioproduction processes. Genomic Vision’s proprietary tools, based on DNA combing technology and artificial intelligence, provide the reliable quantitative measurements needed for high confidence in the characteristics of DNA changes in the genome. These tools are mainly used to monitor DNA replication in a cancer cell, for early detection of cancer and diagnosis of genetic diseases. Genomic Vision, based near Paris in Banjo, is a public quotation listed in Division C of the regulated market Euronext in Paris (Euronext: GV – ISIN: FR0011799907).

For more information, visit www.genomicvision.com

***

Article Art CAC® Medium and small and CAC® Everyone is trading indices

STATEMENT ON PROSPECTS

This press release contains hidden or explicit certain forward-looking statements regarding Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are exposed to many risks, including the risks listed in the “Risk Factors” section of the Universal Registration Document filed with the AMF on 9 February 2021 under No. R.21- 002, available on the Genomic Vision website (www.genomicvision.com), as well as on the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks that Genomic Vision is not yet aware of or that Genomic Vision does not consider material. The occurrence of all or part of such risks may result in actual results, financial conditions, performance or achievements of Genomic Vision differing materially from such forward-looking statements.

This press release and the information contained therein are not and should not be construed as an offer or invitation to sell or subscribe, or a request for any order or an invitation to purchase or subscribe for Genomic Vision shares in any country. Distributing this press release in some countries may be a violation of applicable law. Persons in possession of this press release should be aware of any local restrictions and comply with these restrictions.

View original on businesswire.com: https://www.businesswire.com/news/home/20220217005749/en/

Contacts

Genomic vision
Dominic Remy-Ren
CEO
Tel .: +33 1 49 08 07 51
investisseurs@genomicvision.com

Ulysse communication
Press relations
Bruno Arabian
Tel .: +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor relations
and strategic communications
Tel .: +33 1 44 71 94 94
gv@newcap.eu

Leave a Comment